{
  "Entities": [
    {
      "Name": "Drug",
      "Definition": "Compounds used in the treatment or management of melanoma, particularly those interacting with specific gene mutations.",
      "Sample Data": {
        "Sentence": "Seven drugs including binimetinib and dabrafenib are indicated for the treatment of melanoma with BRAF V600E or V600K mutations.",
        "Annotated": "Drug: binimetinib, dabrafenib"
      }
    },
    {
      "Name": "Gene",
      "Definition": "Genetic elements that can influence the efficacy of drugs in treating diseases like melanoma.",
      "Sample Data": {
        "Sentence": "Melanoma caused by BRAF gene mutation is treated with targeted drugs.",
        "Annotated": "Gene: BRAF gene mutation"
      }
    },
    {
      "Name": "Disease",
      "Definition": "Medical conditions or pathologies, such as melanoma, that are the focus of pharmacogenomic studies.",
      "Sample Data": {
        "Sentence": "Melanoma frequently metastasizes to liver, lungs, and brain.",
        "Annotated": "Disease: Melanoma"
      }
    },
    {
      "Name": "Precise Medication",
      "Definition": "Details on the specific use of medication including population, daily dose, dose form, and frequency.",
      "Sample Data": {
        "Sentence": "The daily dose of afatinib is 40 mg for treating lung cancer.",
        "Annotated": "Precise Medication: afatinib, 40 mg daily"
      }
    },
    {
      "Name": "Adverse Reaction",
      "Definition": "Possible negative effects caused by medications used in pharmacogenomics.",
      "Sample Data": {
        "Sentence": "Potential adverse reactions include nausea and dizziness when taking afatinib.",
        "Annotated": "Adverse Reaction: nausea, dizziness"
      }
    }
  ],
  "Dataset": {
    "Name": "Pharmacogenomics Data for Melanoma",
    "Details": "Data includes drugs, genes, and disease interactions relevant to melanoma treatment, derived from clinical studies and drug labels."
  },
  "Annotation Guidelines": {
    "Description": "Annotations focused on identifying interactions between drugs, genes, and diseases in the context of pharmacogenomics. Entities and relationships were marked based on established pharmacogenomics guidelines.",
    "Link": "Not directly provided in the document."
  }
}
